The United States: New Contours of the Supply Chain for Pharmaceuticals
The United States: New Contours of the Supply Chain for Pharmaceuticals
Читать книгу Download pdf
О чем книга?

The pandemic of COVID-19 has drawn attention to the ways in which the United States depend on critical pharmaceuticals value chains that rely on production based in China and India. China’s role as the primary supplier of APIs (active pharmaceutical ingredient) to global manufacturers of generic, highlights that the U.S. market may be dependent on China API through third markets.

The study of this issue implies the analysis of the main factors inducing the supply chain restructuring and also already outlined approaches to solving this problem.

Over the past few decades, many US pharmaceutical companies have moved finished-dose pharmaceutical production and API (active pharmaceutical ingredients) production over-seas, that driven primarily by the opportunities for lower manufacturing costs and access to growing markets. The adoption of the Drug Price Competition and Patent Term Restoration Act of 1984 played an important role here. This law has opened up the market for generics. Today 90% of prescription drugs sold in the U.S. are generic medications. Despite this, generic drug sales account for less than 25% of prescription drug spending.

However, there is an implicit risk in relying on elaborate global supply chains in which their provision depends on foreign partners. The Covid-19 pandemic has turned these hidden risks into real disruptions. Due to disruptions in the supply chain the United States stepped up efforts to contain the COVID-19 pandemic with limited domestic stockpiles.

The difficulties of 2020 forced the United States to look for options for restructuring supply chain and thus reduce this kind of dependence.

Об авторах

1. A Price Too High Cost, Supply, and Security Threats to Affordable Prescription Drug. A HSGAC MINORITY STAFF REPORT. US Senate Committee on Homeland Securities and Government Affairs. 2019. 59 p. Available at: (accessed 28.05.2021).

2. Gorenstein D. Drug prices: how generics changed the game. July 25, 2017 Available at: (accessed 28.08.2021).

3. Hearing before 112 Congress. First Session. December 7, 2011. 112 p.

4. 2020 Report to Congress of the U.S. - China Economic and Security Review Commission. 116 Congress. Second Session. December, 2020.

5. Woodcock J. Testimony Safeguarding Pharmaceutical Supply Chains in a Global Economy. House Committee on Energy and Commerce. Subcommittee on Health. October 30, 2019. Available at: (accessed 05.07.2021).

6. Ferry J. It’s Time to Rebuild Domestic Drug Production in the US, for Both Health and Economic Reasons. March 17, 2020. Available at: (accessed 25.08.2021).

7. Mullin R. COVID-19 is reshaping the pharmaceutical supply chain. April 27, 2020. Available at (accessed 05.06.2020).

8. The API industry in China: Producing and exporting to the global market. July 1, 2020. Available at:,in%20the%20global%20pharmaceutical%20ecosystem (accessed 23.09.2020).

9. CRS Report. COVID-19: China Medical Supply Chains and Broader Trade Issues. December 23, 2020. 57 p.

10. 2019 Report to Congress of the U.S. - China Economic and Security Review Commission. 116 Congress. First Session. November, 2019.

11. Sheikh K. Essential Drug Supplies for Virus Patients Are Running Low. The New York Times. April 2, 2020. Available at: (accessed 15.09.2021).

12. Congressional Research Service. Pandemic-Related Provisions Expiring in the 117th Congress. May 25, 2021. r.31.

13. Building Resilient Supply Chains, Revitalizing American Manufacturing, and Fostering Broad-Based Growth. 100-Day Reviews under Executive Order 14017. A Report by The White House. June 2021. 250 p. Available at: (accessed 28.08.2021).

14. Jung A., Meade H., Botos M. Re-shoring pharma and medtech manufacturing: playing the long game. EY. October 29, 2020. Available at: (accessed 25.09.2021).

15. Maister Ph. Biden's push to boost resilience of US supply chains. May 5, 2021 Available at: (accessed 16.08.2021).

16. Kearney. Van den Bossche P., Castaño Y., Blaesser B. Serraneau K. Global Pandemic roils 2020 Reshoring Index, shifting focus from reshoring to right-reshoring. Available at: (accessed 15.09.2021).

17. Mullin R. Bringing drug production back to the US. June 29, 2020. Available at: (accessed 23.09.2021).

18. Jaekel B. COVID-19 Vaccine Transforms Pharma Supply Chain Forever. March 15, 2021. Available at: (accessed 27.09.2021).

19. R. Horner. The world needs pharmaceuticals from China and India to beat coronavirus. The Conversation. May 25, 2020. Available at: (accessed 05.09.2021).

20. The Pandemic and the Supply Chain. Addressing Gaps in Pharmaceutical Production and Distribution. Johns Hopkins University. November, 2020.14 p. Available at: (accessed 16.09.2021).

21. Sanchez E., Muzzio F. Reshoring Pharmaceutical Manufacturing to the US: Can We Do It. Pharmaceutical Technology. Vol.45, № 2, 2021. P. 28-30. Available at: (accessed 05.07.2021).